TYRA Tyra Biosciences, Inc.: Rasio Nilai Pasar marang Nilai Buku

TYRA (Tyra Biosciences, Inc.) - tandha merek perusahaan

The price action for Tyra Biosciences, Inc. (TYRA) on GURU.Markets reflects the dynamics of an asset operating amidst intense competition for intellectual property and talent, where the success of other developers could potentially nullify project value. The current indicator is 3.67. The business relies on diversified component supply chains, ensuring high returns and stable logistics. Clinical trials are fully outsourced to external contractors through a streamlined vendor management system.

Rasio Kapitalisasi marang Nilai Buku Tyra Corp (TYRA): kanggo periode 04.07.2022 - 29.10.2026

Rincian analitis perusahaan Tyra Biosciences, Inc.

- rega saham lan prakiraan rega para ahli:
Rega saham Tyra Biosciences, Inc.|TYRA - Prakiraan konsensus analis
- data kapitalisasi saham perusahaan:
Nilai pasar Tyra Bio|TYRA - Total Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Tyra Biosciences|TYRA - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku tyra.bio|TYRA - Gunggung Aset Perusahaan
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Tyra Biosciences, Inc.|TYRA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Tyra Bio|TYRA - Utang perusahaan|Rasio utang marang kapitalisasi buku Tyra Bio|TYRA - Utang jangka dawa|Utang jangka cendhak perusahaan Tyra Biosciences|Indikator likuiditas cepet tyra.bio
- rincian bathi lan kelipatan pasar:
TYRA - Penghasilan resik perusahaan
Pambiji fundamental:Tyra Biosciences, Inc.
Produk asil prodhuksi Tyra Bio

The Market-to-Book ratio measures the premium of market value over net assets, reflecting investor expectations regarding future earnings and intangible advantages. By analyzing the valuation dynamics of market capitalization relative to the balance sheet, we see how the potential of FGFR inhibitors and the success of the drug TYRA-300 in bladder cancer therapy create high value for Tyra Biosciences, Inc. (TYRA), significantly exceeding its formal book value.

Analisis perusahaan pesaing

GMAB: Rasio Kapitalisasi Pasar marang Nilai Buku|exelixis.com (EXEL) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Nuvalent|Koefisien Nilai Pasar marang Nilai Buku Kymera Therapeutics, Inc. KYMR|Rasio Nilai Pasar marang Nilai Buku IDEAYA Bio (IDYA)|Enliven Corp - Rasio Kapitalisasi marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku ORIC (ORIC Pharmaceuticals)|RLAY - Rasio Kapitalisasi marang Aset Bersih|NRIX - Rasio Nilai Pasar marang Nilai Buku|Koefisien Nilai Pasar marang Nilai Buku Verastem Oncology|Monte Rosa Tx (GLUE) - Rasio Nilai Pasar marang Nilai Buku|CGEM (Cullinan Corp) - Rasio Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Immuneering Corporation|Koefisien Nilai Pasar marang Nilai Buku c4therapeutics.com CCCC|Rasio Kapitalisasi Pasar marang Nilai Buku BDTX|Repare Therapeutics, Inc. (RPTX) - Rasio Nilai Pasar marang Ekuitas|PMV Pharma - Rasio Kapitalisasi marang Aset Bersih|Karyopharm Therapeutics, Inc. (KPTI) - Koefisien Nilai Pasar marang Nilai Buku|PPCB: Rasio Kapitalisasi marang Aset Bersih|Nilai Pasar marang Nilai Buku BGMS (cyclacel.com)|AADI (aadibio.com) - Rasio Kapitalisasi marang Aset Bersih|ALRN: Multiplikator Kapitalisasi Pasar marang Nilai Buku|BPMC (Blueprint Medicines Corp.) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku GlycoMimetics Corp|Rasio Nilai Pasar marang Nilai Buku SpringWorks Therapeutics (SWTX)